FDA delays decision on Orexigen's obesity drug by three months
June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its shares down about 12 percent in premarket trading.
The regulator, which rejected the drug in 2011, indicated the extension is associated with potential post-marketing obligations and set Sept. 11 as its new date for review.
The FDA had asked the company to conduct additional trials on the drug, citing potential heart risks.
An interim analysis of the latest 8,900-patient study showed that overweight and obese patients receiving contrave did not have a higher heart risk, compared with those on a placebo, the company said in November. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)
- Restraint marks Ferguson, Missouri protests for third straight night |
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |
- Merkel says tightening Ukraine-Russian border is key to peace deal |
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- U.S. hostage rescuers dropped from night sky: Syria activist